Collegium Pharmaceutical, Inc. Announces FDA Filing for AllerNase(TM), a Nasal Inhaled Steroid for the Treatment of Allergic Rhinitis

CUMBERLAND, R.I.--(BUSINESS WIRE)--Collegium Pharmaceutical, Inc., a specialty pharmaceutical company with a focus on respiratory and CNS disorders, today announced that it filed a Supplemental New Drug Application (sNDA) with the U.S. Federal Drug Administration (FDA) for the approval of AllerNaseā„¢ (triamcinolone acetonide, USP) Nasal Spray, 50 mcg, an aqueous based intranasal steroid indicated for the once daily treatment of nasal symptoms associated with both seasonal and perennial allergic rhinitis in adults and children twelve years of age and older.

Back to news